Blood disease

| CRISPR Medicine | This is an overview of articles related to blood disorders

Blood disease

| CRISPR Medicine | This is an overview of articles related to blood disorders

Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT05329649)
Sponsors:
Vertex Pharmaceuticals Incorporated
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion Dependent Beta-Thalassaemia, TDT, (ChiCTR2100052858)
Sponsors:
923rd Hospital of The People's Liberation Army 
Indicator
IND Enabling
Phase I
Phase II
Phase III
Transfusion Dependent Beta-Thalassaemia, TDT, (ChiCTR2100053406)
Sponsors:
The First Affiliated Hospital, Guangxi Medical University  
Indicator
IND Enabling
Phase I
Phase II
Phase III
Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (2018-001320-19)
Sponsors:
Vertex Pharmaceuticals Incorporated
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04774536)
Sponsors:
Principal Investigator: Mark Walters, MD UCSF Benioff Children's Hospital Oakland
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine